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Summary
Background: Oxaliplatin is a new cytotoxic agent from the
diaminocyclohexane family with proven antitumor activity
against colon cancer cell lines. Activity in patients with colo-
rectal carcinoma previously treated with 5-fluorouracil has
been studied in three single-agent phase II trials, showing a
reproducible response rate of 10%. Here we report a phase II
trial with oxaliplatin as a first-line chemotherapy for meta-
static colorectal cancer.
Patients and methods: Twenty-five patients were entered in
the study. All of them had metastatic disease without previous
chemotherapy, and at least one lesion had to be measurable by
computed tomography (CT). Therapy consisted of a two-hour
infusion of oxaliplatin at a dose of 130 mg/m2 every 21 days.
Results: The overall response rate determined by investiga-
tors was 20% (95% CI, 6.8%-40.7%). Eight patients (32%) had
stable disease. The median time to disease progression in res-
ponders was six months (range four to nine). The median
progression-free survival was four months and median overall
survival 14.5 months (95% CI, 10-20 months). The main toxic
effects were peripheral neuropathy (92%) and laryngophar-
yngeal dysesthesia (75%). No severe grade 3-4 neurotoxicities
(NCI-CTC) were found. Gastrointestinal and hematological
toxicities were mild.
Conclusions: Oxaliplatin is an active agent in first-line che-
motherapy for advanced colorectal cancer. It was well tolerated,
caused no toxic deaths, had low hematotoxicity, well controlled
gastrointestinal toxicity, and frequent but mild peripheral
neurological symptoms. Therefore, it is of interest to associate
oxaliplatin with other active compounds.
Key words: advanced colorectal carcinoma, oxaliplatin, phase II
study
Introduction
Colorectal cancer is the second most frequent cause of
cancer-related mortality in the Western world [1]. Early
detection and radical surgery will be curative for 50% of
those patients diagnosed in a non-metastatic stage of
the disease. Furthermore, adjuvant chemotherapy has
proved to reduce disease recurrence and to improve sur-
vival for this group of patients [2-4],
Nevertheless, an important number of patients still
needs palliative chemotherapy treatment for metastatic
disease.
The most widely used chemotherapy agent for patients
with colorectal cancer during the past 30 years has been
5-fluorouracil (5-FU). Recent studies have demonstrated
that the addition of leucovorin enhances 5-FU cytotox-
icity with higher response rates, but without improve-
ment of overall survival [5]. Other combination chemo-
therapies such as cisplatin have failed to demonstrate an
advantage in response rate or survival, while having a
considerable increase of toxicity [6].
Oxaliplatin is a new platinum complex, diaminocy-
clohexane (DACH) compound, with proven antitumor
activity against colon cancer cell lines [7]. Toxic effects
of oxaliplatin include sensitive neuropathy, vomiting,
diarrhea and mild myelosuppression. There is no renal
toxicity [8]. The activity of oxaliplatin single agent in
metastatic colorectal patients who have progressed on
5-FU has been recently studied in three different phase
II trials, with a 10% response rate in all three of them
[9, 10].
The data of this phase II study which aimed to deter-
mine the activity of single-agent oxaliplatin as first-line
treatment in metastatic colorectal cancer are presented
and discussed.
Patients and methods
Patients
From June 1994 to November 1995, 25 patients diagnosed with meta-
static colorectal adenocarcinoma, were included in a multicenter phase
II study. Patient characteristics are listed in Table 1. The eligibility
criteria were: all patients were required to have histologic evidence of
metastatic colorectal cancer; no previous chemotherapy for advanced
disease, except prior adjuvant chemotherapy if it had been completed
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/9/1/105/222964 by D
ivisione C
oordinam
ento Biblioteche U
N
I M
ilano user on 09 July 2019
106
Table 1. Patients characteristics.
Total number of patients
Age
Median
Range
Sex
Male
Female
Performance Status (ECOG)
0
1
Grade of differentiation
Highly differentiated
Moderately differentiated
Undifferentiated
Unknown
Sites of tumor involvement
Liver only
Liver and other sites
Lung only
Lymph nodes only
Other multiple sites
25
60
38-70
17
12
13
4
13
2
6
10
2
1
4
Number of sites of metastatic tumor involvement
1 11
2 6
3 6
>3 2
CEA tumor marker blood level
<10ng/ml 9
>10ng/ml 13
Unknown 3
CA 19.9 tumor marker level
< 60 IU/1 6
>60IU/l 10
Unknown 9
Previous treatment
Adjuvant radiotherapy 1
Adjuvant chemotherapy 6
Adjuvant chemotherapy + radiotherapy 1
at least 12 months before study entry; at least one lesion had to be
measurable in two dimensions by computed tomography (CT); age
between 18 and 70 years; ECOG performance status 0-1; absence of
peripheral neuropathy; medullar, hepatic and renal function in normal
range; written informed consent was required prior to start of treat-
ment. Patient with the following conditions were not eligible: severe
organ dysfunction, uncontrolled hypercalcemia, other prior primary
cancers except basal cell epithelioma, in situ cervix uteri carcinoma,
complete or partial intestinal obstruction, severe neurologic or psychi-
atric disease, and women of childbearing age, with potential for
fertilization (using no contraceptive method) or who were lactating.
Treatment
Therapy consisted of a two-hour, infusion of oxaliplatin (Debiopharm
S.A., Lausanne, Switzerland) at a dose of 130 mg/m2, repeated every
21 days. The drug was dissolved in 250-500 ml of a 5% glucose
solution. All patients received a minimum of three treatment courses
and a maximum of six courses when stable or responding after the
third course; progression of the disease or severe toxicity led to patient
withdrawal. The dose of oxaliplatin was reduced by 25% in instances of
NCI grade 3 neutropenia, thrombocytopenia, or peripheral neuro-
toxicity, or grade 2 renal toxicity. In case of grade 4 neutropenia,
thrombocytopenia or grade 3 renal toxicity, the dose was reduced by
50%. Any grade 4 non-hematological toxicity led to discontinuation of
the treatment. Patients were given prophylactic and curative antiemetic
treatment if required.
Patient evaluation
Before each treatment course, all patients gave a complete medical
history and underwent a physical examination. Laboratory tests in-
cluding hemogram, biochemistry, CEA and CA 19.9 were performed
and toxicity monitored before each cycle, using NCI-CTC criteria.
The antitumor response was evaluated every three cycles by CT scan,
according to the WHO criteria. The response was validated by an
expert committee of radiologists independent of the study. The time to
disease progression was calculated from the date of initiation of therapy
to the date of progression of disease. Overall survival was calculated
from the date of initiation of therapy to that of patient's death. Survival
analysis was performed by the Kaplan-Meier method.
Results
The 25 patients included in the study were evaluated
for response and toxicity. They received 123 cycles, 119
(96.7%) of them were given at the full dose of 130 mg/m2
and only four at reduced doses. The median number of
cycles per patient was five (range one to nine). Twelve
patients received at least six cycles, although one patient
received the sixth cycle incompletely because of a hyper-
sensitivity reaction during the treatment. The other 13
patients could not receive six cycles of chemotherapy
because of progression of the disease. The median dose
intensity of oxaliplatin was 43.3 mg/m2/week (range
30.7—44.0), and the median cumulative dose per patient
was 650 mg/m2 (range 130-1170).
Efficacy
The overall response rate found by investigators was
20% (95% CI, 6.8%-40.7%) (one CR + four PR). Eight
patients (32%) had disease stabilization and 12 (48%)
had progressed. For the expert committee of radiologists
independent of the study, the response rate was 12%
(three PR, 12 SD, eight PD). The median time to disease
progression in responders was six months (range four to
nine). The median progression-free survival (PFS) was
four months (range two to seven), and median overall
survival was 14.5 months (95% CI, 10-20 months).
Toxicity
The 25 included patients received at least one cycle of
oxaliplatin, and all of them were therefore evaluated for
toxicity. Only one patient (4%) had to discontinue the
treatment prematurely because of toxicity, when in the
sixth cycle he showed a generalized erythema 15 minutes
after the infusion had started. The same symptomatol-
ogy occurred again when one week later the treatment
was reinitiated. In both occurrences corticosteroid treat-
ment controlled the symptoms.
The main toxic effects are shown in Table 2. Periph-
eral neuropathy (92%) and laryngopharyngeal dysesthe-
sia (75%) were the side effects most often observed.
However, no severe grade 3-4 neurotoxicity (NCI-CTC)
was observed except in one patient who presented with
laryngopharyngeal dysesthesia, and severe dyspnea after
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Table 2. Toxic effects by patient.
Toxic effect NCI-CTC
Neutropenia
Thrombocytopenia
Anemia
Peripheral neuropathy
Vomiting
Diarrhea
1
2 (8%)
4(16%)
19 (76%)
16(67%)
1 (4%)
7 (29%)
2
3 (12%)
2 (8%)
1 (4%)
6 (25%)
2 (8%)
0
3
0
0
0
0
2 (8%)
1 (4%)
4
0
0
0
0
1 (4%)
0
oxaliplatin administration, and had to be admitted to
hospital. This patient did not withdraw from the study
and was administered full-dose oxaliplatin in the suc-
ceeding cycle in a 360-minute infusion without recur-
rence of the symptoms. The median time preceding the
appearance of symptoms was one cycle. The median
time of recovery from sensitive neuropathy was nine
weeks after chemotherapy treatment was discontinued.
Other mild neurologic side effects were cramps,
Lhermitte's sign (momentary, electrical shock-line par-
esthesias from the neck to the extremities, precipited by
neck flexion) and abolition of osteotendinous reflexes.
Nausea and vomiting were frequent (56% and 24%, re-
spectively) but of only mild-moderate severity, although
92% of patients received prophylactic anti 5-HT3 treat-
ment. Moderate diarrhea occurred in eight patients (33%).
No grade 4 diarrhea was observed. Hematological tox-
icity was mild, with no grade 3-4 anemia, neutropenia
or thrombocytopenia.
Discusssion
Oxaliplatin is a new platinum derivative with proven
activity in colon cancer, in in vitro [7] and in clinical
phase I studies [8]. The recommended dose for phase II
studies, was 130 mg/m2 in short infusion every three
weeks. Dose-limiting toxicity is peripheral neuropathy,
namely, cumulative and reversible dysesthesia and /or
paresthesia.
Up to now, three phase II studies with oxaliplatin as a
second-line treatment, in patients who have progressed
on fluoropyrimidines, have been carried out, with a 10%
response rate in the three of them [9, 10]. In the present
study, in patients with no previous chemotherapy the
objective response rate determined by investigators was
20% (one CR, four PR), similar to 5-FU plus leucovorin
and superior to 5-FU alone, according to Advanced
Colorectal Cancer Meta-Analysis Project [5] data. The
responses were reviewed by an expert committee of
radiologists independent of the study, who found a
response rate of 12%. The lack of clinical data about the
patients, as well as of the tumor marker blood levels for
the committee of radiologists may explain the divergence
between the two assessments. The positive clinical and
biological evolution could have influenced the investiga-
tors in two cases in which radiological shrinkage was
close to the limit of 50%; for the expert radiologists, it
did not reach the 50% threshold and they therefore
considered the response as a stabilization. The patient
judged to have a complete response by investigators had
residual lesion according to the radiologists. Preliminary
results reported recently by Becouarn et al. confirm the
activity of oxaliplatin as single agent in untreated colo-
rectal adenocarcinoma (24% PR) [11].
As in the former studies, oxaliplatin was well toler-
ated. Only one patient showed a serious side effect
related to the drug, the major symptoms of which were
severe dyspnea and laryngopharyngeal dysesthesia. This
toxicity was averted in the succeeding cycles with a
longer time of infusion (360 minutes). No grade 3-4
anemia, neutropenia or thrombocytopenia were ob-
served, and neither blood transfusion, patient antibiotic
intake due to febrile neutropenia nor dose reduction
were required. The most frequently occurring toxicity
was neurologic, in terms of paresthesias and laryngo-
pharyngeal dysesthesias (92% and 75%, respectively).
No case of grade 3 was observed (functional interfer-
ence) and there was no requirement for delay of the cycle
or dose reduction. The acute gastrointestinal toxicity
was moderate. Due to the high emetic potential of
platinum compounds, almost all patients received pro-
phylactic treatment by serotonin antagonists. Only three
patients (12%) presented grade 3-4 vomiting in four
cycles (3%). No alopecia, ototoxicity or nephrotoxicity
were seen, which clearly demonstrates a different profile
of toxicity from that of cisplatin.
At present, two new drugs have been shown to be
active in metastatic colorectal cancer, irinotecan and
raltitrexed. Phase II studies with irinotecan have shown
15%—32% response rate for both groups of patients,
without previous chemotherapy or pretreated with 5-FU
[12]. A recent study with 213 patients with and without
previous treatment with 5-FU has shown a 17.7% and a
18.5% response rate, respectively [13]. Even though tox-
icity in general was moderate, there was 48% grade 3-4
neutropenia and 35% grade 3-4 diarrhea as a main
toxicity. Raltitrexed, a specific inhibitor of thymidylate
synthase, showed a response rate of 29% [14] in a phase
II study involving 177 patients, and in a recent compara-
tive phase III study versus 5-FU plus leucovorin the
response rate was 19.8%, with a good tolerance, except
for grade 3-4 elevation of SGOTand/or SGPT in 10% of
patients [15].
In conclusion, oxaliplatin at a dose of 130 mg/m2
every three weeks as a first-line treatment in metastatic
colorectal cancer patients has a moderate activity, sim-
ilar to that of 5-FU plus leucovorin, irinotecan or ralti-
trexed, with a good tolerance and a very different profile
of toxicity from these other drugs. Therefore, it is of
interest to associate oxaliplatin with one or several of
these compounds.
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